AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

The F.D.A. authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...

Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan ...

Arab Finance: AstraZeneca Egypt is planning to inject $50 million into new investments in Egypt, equivalent to nearly 50% of the company’s capital, the firm’s Country President Hatem Werdany stated.